Summary. Embryonic development involves the establishment of new patterns of vascular growth in the fetus and within the lining of the womb. A factor, human uterine angiogenesis factor, has been purified from the decidua and stimulates the growth of blood vessels in collagen sponge implants and in the chick chorioallantoic membrane. Evidence is presented that suggests that a major active component of human uterine angiogenesis factor is an activator of latent matrix metalloproteinases, of low Mr, called endothelial-cell-stimulating angiogenesis factor and that this factor is present in substantial quantities in a number of embryonic tissues.
Introduction
Embryological development involves the establishment of two new networks of blood vessels, one produced by the embryo itself and one arising within the lining of the womb (decidua) in response to the growing demands of the developing fetus. Growth factors are known to play a critical role in the control of embryological development (Mercóla & Stiles, 1988) and the presence of angiogenic activity in fetal tissues has been demonstrated (Burgos, 1983; Gospodarowicz et ai, 1985) and ascribed to fibroblast growth factors. Human uterine angiogenesis factor (HUAF), an extract derived from decidua obtained from first trimester legal terminations of pregnancy, induced neovascularization of the chorioallantoic membrane (Maroudas et ai, 1987) and vascularization of collagen sponge implants (Lindenbaum et al., 1989) . The active components of this extract are known to be of MT 30 000 or less and one has been identified as fibroblast growth factor (FGF) (Lindenbaum et al, 1989 ).
Endothelial-cell-stimulating angiogenesis factor (ESAF) is a nonprotein, microvessel, cellspecific mitogen of low M" which is capable of activating latent matrix metalloproteinases by dissociating the complexes formed with tissue inhibitor of metalloproteinases (TIMP) and also of activating promatrix metalloproteinases (McLaughlin et al, 1991) . This factor occurs in high con¬ centrations where angiogenesis is occurring, such as in conditions of proliferative retinopathy (Taylor et ai, 1986 (Taylor et ai, , 1989 or in the epiphyseal growth plate (Brown et al, 1987) . Significant synergism exists between ESAF and FGF in the stimulation of cultured microvessel endothelial cells (Odedra & Weiss, 1987) and tissues rich in FGFs tend to contain high concentrations of ESAF (Taylor et al, 1988 Comparison of ESAF from decidua and HUAF with ESAF from other sources A single sample (5 ml) of ESAF extract from HUAF was purified by HPLC and its elution profile was compared with that from bovine and human pineal glands, synovial fluid and serum.
Angiogenic activity in vivo of ESAF from decidua and HUAF ESAF purified by HPLC was applied to a chick yolk sac membrane to confirm angiogenic activity.
Results
Both bovine and human decidua contained concentrations of ESAF comparable to those in other highly vascular tissues, such as brain and kidney (Fig. 1) , but contained considerably less than the pineal gland (Taylor et al, 1988) . Extraction of ESAF from HUAF increased its specific activity significantly, giving 1-6 + 0-28 units of ESAF/mg protein compared with 0-2 + 0-04 units of ESAF/mg protein. ESAF extracted from HUAF was identical to ESAF isolated from other sources in terms of its behaviour on HPLC. After purification, the active fraction eluted at 8 min from the final reverse-phase HPLC column, which is a time identical to that of ESAF purified from all other tissue sources (Fig. 2) Gestational age (days) Fig. 3 . Concentrations of endothelial-cell-stimulating angiogenesis factor (ESAF) in developing bovine tissues in relation to gestational age of the fetus: (a) brain, (b) growth plate and (c) diaphysis.
Extraction of ESAF from fetal bovine tissues showed a decline in concentration with increasing gestational age in the brain, diaphysis and epiphyseal growth plate (Fig. 3) .
Discussion
Fibroblast growth factor is a major active component of HUAF (Lindenbaum et ai, 1989) . We now show that ESAF is another major component of HUAF, suggesting that these two angiogenic molecules are co-distributing. In decidua a dramatic increase in the density and number of blood vessels occurs during the first trimester. The co-occurrence of ESAF and FGFs might be expected to direct the mitogenic activity of these latter factors towards the stimulation of blood vessel growth, as synergism has been reported between ESAF and basic FGF in the stimulation of microvessel endothelial cell growth in vitro (Odedra & Weiss, 1987) ; the same synergistic effect has been observed in vivo on the chick yolk sac membrane (Odedra & Weiss, 1991) . Co-distribution of ESAF and FGF occurs in other situations; the tumour angiogenesis factor described by Folkman et al. (1971) is now known to contain FGFs and ESAF as its active components (Weiss et al, 1979; Klagsbrun et al, 1986) . Neither ESAF nor FGF alone has as great an activity in vivo as a mixture of the two (Odedra & Weiss, 1991) and comparable results have been found in vitro using cultured microvessel endothelial cells (Odedra & Weiss, 1987 The high concentrations of ESAF detected in first-trimester human and bovine decidua may reflect the intense vascularization that occurs during this period and this is confirmed in the three fetal bovine tissues investigated, in which concentrations of ESAF declined after the first trimester (Fig. 3) . ESAF may have a role in changes that occur in the cervix at parturition. Studies by Raynes et al (1988a) suggest that collagenase activity in the cervix is low and does not increase during pregnancy. This may be due, in part, to the presence of substantial and increasing quantities of TIMP in the cervix (Raynes et al, 1988b) causing most of any collagenase present to be in the form of a TIMP-collagenase complex. Such collagenase cannot be activated by aminophenylmercuric acetate and so is effectively silent in any assay system. That concentrations of collagenase in human cervix and lower uterine segment increase approximately tenfold during labour (Rajabi et ai, 1988) suggests either a rapid increase in the synthesis of collagenase at the expense of its inhibitor or the activation of indigenous collagenase complexes. ESAF is the only biological agent shown to be capable of dissociating this complex and releasing active collagenase molecules (McLaughlin et al., 1991) . It is therefore possible that ESAF is involved in cervical changes during labour because of its ability to activate complexed collagenase in the extracellular matrix.
